Andere Sprachen Keymed Biosciences Inc.

Aktien

A3CTJD

KYG5252B1023

2162

Verzögert Hong Kong S.E. Andere Börsenplätze 09:56:34 13.05.2024			% 5 Tage	% 1. Jan.
41,5 ^HKD	+2,60 %		+16,29 %	-15,68 %

30.04.	NDA-Antrag von Keymed Biosciences für Allergiebehandlung von der NMPA akzeptiert	MT
28.04.	Keymed Biosciences Inc. kündigt klinische Phase-III-Studie mit Stapokibart-Injektion zur Behandlung von saisonaler allergischer Rhinitis an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA	30.04.
Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points	29.04.
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Stapokibart Injection for the Treatment of Seasonal Allergic Rhinitis	28.04.
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	12.04.
KeyMed Biosciences’ Attributable Loss Widens in 2023	27.03.
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Keymed Biosciences Buys Back Shares	22.01.
Keymed's Rhinosinusitis Treatment Achieves Primary Endpoints; Shares Rise 5%	27.12.
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps	27.12.
China Accepts New Drug Application for Keymed Biosciences' Atopic Dermatitis Injection; Shares Rise 4%	07.12.
Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection	07.12.
Keymed Presents Phase 1 Trial Data for Gastric/Gastroesophageal Cancer Drug	08.11.
Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901	08.11.
Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023	11.10.23
Keymed Biosciences’ Profit Surges in H1	25.08.23
Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	24.08.23
Keymed Biosciences to Acquire 18.7% of Kangnuo Xing for 150.6 Million Yuan	27.06.23
Keymed Presents Data on Phase 1 Study for Lymphoma, Myeloma Drug; Shares Fall 4%	12.06.23
Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313	12.06.23
Keymed Biosciences Completes Data Unblinding for Phase 3 Study of Eczema Treatment; Shares Rise 8%	30.05.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Keymed Biosciences Inc.

Aktien

A3CTJD

KYG5252B1023

2162

Andere Sprachen

Filter